Laura Calvo‐Barreiro

This paper identifies DELC2, a brain-penetrant CHI3L1 inhibitor, which reduces neuroinflammation and amyloid-β levels in Alzheimer's disease models.

This paper identifies BA59, an androstane-triol derivative, as a potent immunomodulator that reduces disease severity in experimental autoimmune encephalomyelitis by modulating T cell balance and antigen-presenting cell function.

This paper uses fragment-based screening to identify small molecules that bind to the CD28 receptor, demonstrating a successful approach for targeting its PPI interface.

This paper identifies a small molecule inhibitor of CHI3L1, DEL-C1, which modulates neuroinflammation in Alzheimer's disease through multiple validated mechanisms.

HTS-Oracle uses AI to prioritize small molecule hits for challenging immune targets, reducing screening needs and increasing hit rates significantly.

This paper identifies first-in-class small molecule agonists of TREM2 through DEL screening, validates their binding and function, and suggests a novel activation mechanism.

This paper develops an SPR-based HTS workflow to identify CD28-targeted small molecules, finding three compounds with micromolar affinities and functional inhibition of CD28-CD80 interaction.

This paper identifies and optimizes a potent small molecule LAG-3 inhibitor using DNA-encoded chemical library screening for cancer immunotherapy.

HTS-Oracle improves hit identification for difficult-to-drug targets by using a deep learning platform that integrates molecular embeddings and cheminformatics features, achieving an 8.4% hit rate with reduced screening costs.

This study develops a TRIC-based HTS platform to identify small molecule CD28 binders, finding 12 validated candidates with micromolar affinities.

This paper discovers and validates a first-in-class small molecule inhibitor of the SLIT2/ROBO1 interaction using DNA-encoded library screening and demonstrates its functional inhibition and ADME properties.

The paper identifies two small molecule ligands for LAG-3 through virtual screening and experimental validation, with one showing cellular target engagement.

The paper designs and characterizes second-generation cyclic peptide LAG-3 inhibitors, identifying cyclic peptide 12 as the most effective with an IC50 of 4.45 µM.

This paper discovers small molecules targeting ICOS using ASMS screening and identifies key structural features for ICOS/ICOS-L inhibition.